Lamyaa M. Kassem, Mohamed EA Abdelrahim, Hassan F. Naguib

Investigating the Efficacy and Safety of Silymarin in Management of Hyperbilirubinemia in Neonatal Jaundice

Unconjugated hyperbilirubinemia (UCB) is one of the most common conditions in neonates. Conventional treatment consists of phototherapy and exchange transfusion. Phototherapy is safe and effective but it has several disadvantages. Exchange transfusion is associated with a significant morbidity and even mortality. That indicates the need to develop an alternative pharmacological treatment strategies. It should be less invasive and at least as effective and safe as phototherapy. Herbal therapy has recently received special attention. Silymarin herbal drug has laxative, antioxidant, anti-inflammatory, hepatic protective, regenerative and enhancing of glucoronidation activities. The study presented here aimed to investigate effect of Silymarin on duration of phototherapy. A prospective cohort trial performed on 170 full term healthy neonates with UCB, 85 received oral 3.75mg/kg of Silymarin twice daily plus phototherapy and 85 neonates received only phototherapy. Total serum bilirubin (TSB) was measured every 24h, Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and albumin were measured before and after therapy for both groups. The mean duration of phototherapy was found to be significantly reduced from 5.3 ± 0.82 days in the control group to 4.2 ± 0.76 days in Silymarin-treated group (p=0.001). ALT, AST are improved to normal levels significantly (p=.001) also albumin (p=0.005). Silymarin dose of 3.75mg/kg twice daily along with phototherapy was more effective than phototherapy alone in treating full term healthy neonates with UCB.

Keywords:

silymarin, neonatal jaundice hyperbilirubinemia, phototherapy, bilirubin,

PDF

___

1. Cohen RS, Wong RJ, Stevenson DK. Understanding neonatal jaundice: a perspective on causation. Pediatrics & Neonatology. 2010;51(3):143-8. doi: 10.1016/S1875- 9572(10)60027-7
2. Cloherty JP, Eichenwald EC, Stark AR, eds. Manual of Neonatal Care. 6 ed. 2008;181-212.
3. Stevenson DK, Vreman HJ, Oh W, Fanaroff AA, Wright LL, Lemons JA, Verter J, Shankaran S, Tyson JE, Korones SB, Bilirubin production in healthy term infants as measured by carbon monoxide in breath. Clinical chemistry. 1994;40(10):1934-9.
4. Yudkin S, Gellis SS. Liver function in newborn infants with special reference to excretion of bromsulphalein. Archives of disease in childhood. 1949; 24(117):12-4.
5. Tazawa Y, Abukawa D, Watabe M, Nakagawa M, Yamada M. Abnormal results of biochemical liver function tests in breast-fed infants with prolonged indirect hyperbilirubinaemia. European journal of pediatrics. 1991;150(5):310-3.
6. Bhutani, VK, Johnson LH, Maisels MJ, Newman TB, Phibbs C, Stark AR, YearginAllsopp M. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. Journal of perinatology. 2004;24(10):650-62.
7. Maisels M.. Physiologic jaundice. Avery's Neonatology Pathophysiology & Management of the Newborn. 6th Edition. Philedelphia Lippincott Saunders. 2005;768-846.
8. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001;344(8):581-90.
9. Dennery PA. Pharmacological interventions for the treatment of neonatal jaundice. Elsevier. 2002.
10. Avery GB, MacDonald MG, Seshia MMK, Mullett MD, Avery's neonatology: pathophysiology & management of the newborn. Lippincott williams & wilkins. 2005.
11. Tiribelli C, Ostrow JD, New concepts in bilirubin and jaundice: Report of the Third International Bilirubin Workshop, April 6‐8, 1995, Trieste, Italy. Hepatology. 1996;24(5):1296-311.
12. Cuperus F, Hafkamp A, Hulzebos C, Verkade H. Pharmacological therapies for unconjugated hyperbilirubinemia. Current Pharmaceutical Design. 2009;15(25):2927- 38.
13. Tamayo C, Diamond S. Review of Clinical Trials Evaluating Safety and Efficacy of Milk Thistle (Silybum marianum [L.] Gaertn.). Integrative cancer therapies. 2007;6(2): 146-57.
14. Morazzoni P, Bombardelli E. Silybum marianum (fitoterapia). Fitoterapia. 1995;66:3- 42.
15. Křen V Walterová D. Silybin and silymarin--new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005 Jun;149(1):29-41.
16. Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005 Nov;12(6):559-67.
17. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, Garcea G, Farmer PB, Steward WP, Gescher AJ. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res. 2006 May 1;12(9):2944-50.
18. Farhat R, Rajab M. Length of postnatal hospital stay in healthy newborns and rehospitalization following early discharge. N Am J Med Sci. 2011 Mar;3(3):146-51. doi: 10.4297/najms.2011.3146.
19. Lin SC, Shyur SD, Huang LH, Wu JY, Chuo HT, Lee HC. Neonatal lupus erythematosus with cholestatic hepatitis. J Microbiol Immunol Infect. 2004 Apr;37(2):131-4.
20. Maisels, M., R. Baltz, V. Bhutani, T. Newman, H. Palmer, and W. Rosenfeld, Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297-316.
21. Maurer HM, Wolff JA, Finster M, Poppers PJ, Pantuck E, Kuntzman R, Conney AH. Reduction in concentration of total serum-bilirubin in offspring of women treated with phenobarbitone during pregnancy. Lancet. 1968;292(7560):122-4.
22. Brown AK, Kim MH, Wu PY, Bryla DA. Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia. Pediatrics. 1985;75(2):393-400.
23. Carvalho MD. Treatment of neonatal hyperbilirubinemia. J Pediatr (Rio J). 2001 Jul;77 Suppl 1:S71-80. Portuguese.
24. Javed S, Kohli K, Ali M. Patented Bioavailability Enhancement Techniques of Silymarin. Recent Pat Drug Deliv Formul. 2010 Jun;4(2):145-52. Review.
25. Horne SH, Milk Thistle. natures field. 2006;22(8).
26. Ghosh A, Ghosh T, Jain S. Silymarin-A review on the Pharmacodynamics and Bioavailability Enhancement Approaches. Journal of Pharmaceutical Science and Technology. 2010;2.
27. Radko L, Cybulski W. Application of silymarin in human and animal medicine. J PreClin Clin Res. 2007;1:22-6.
28. Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther. 2007 Jun;6(2):104-9. Review.
29. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs. 2001;15(7):465-89.
30. Lyon LM, The Handbook of Clinically Tested Herbal Remedies. Economic Botany. 2005;59(2):210-1.
31. Touw DJ, Graafland O, Cranendonk A, Vermeulen RJ, van Weissenbruch MM. Clinical pharmacokinetics of phenobarbital in neonates. Eur J Pharm Sci. 2000 Dec;12(2):111-6.
32. Pitlick W, Painter M, Pippenger C. Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther. 1978 Mar;23(3):346-50.
33. Heimann G, Gladtke E. Pharmacokinetics of phenobarbital in childhood. Eur J Clin Pharmacol. 1977 Dec 2;12(4):305-10.
34. Dixit N, Baboota S, Kohli K, Ahmad S, Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian journal of pharmacology. 2007;39(4):172-9.